
    
      This is a prospective, randomized, 2-arm, Phrase 2, superiority and multicenter study.
      HER2-positive breast cancer patients with active refractory brain metastases are included.
      There will be two group: Group A (Trastuzumab, Taxanes and Pertuzumab) and Group B
      (Trastuzumab, Taxanes and TKIs). The primary outcome is objective response rate (ORR).
    
  